A Study to Evaluate the Effects of Apremilast on QTc Interval in Healthy Male Subjects

Trial Profile

A Study to Evaluate the Effects of Apremilast on QTc Interval in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Apremilast (Primary) ; Moxifloxacin
  • Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 20 Jun 2016 New trial record
    • 10 Jun 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top